← SynDRA
PALOSURAN
SynDRA canonical compound SYN0020310 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | UTS2R |
|---|
| Mechanism of action | urotensin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- UTS2R ANTAGONIST
- Urotensin II receptor antagonist
- urotensin receptor antagonist
- UTS2R INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SIGMAR1
- SLC6A4
- HTR2C
- HTR2B
- SLC6A2
- HTR2A
- DRD2
- ADRA2A
- TMEM97
- HTR1D
- HTR1E
- MPG
- HTR3A
- HTR5A
- HTR6
- HTR7
- MBD4
- ADGRF1
- NTHL1
- MUTYH
- NEIL2
- HTR1A
- OGG1
- OPRD1
- OPRK1
- OPRM1
- S1PR1
- SLC6A3
- TDG
- TSPO
- HTR1B
- HRH3
- HRH4
- CHRM4
- ADRA1B
- ADRA1D
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2D6
- CP3A7
- GAMT
- GNMT
- HNMT
- NNMT
- PNMT
Cross-references
Synonyms
- Act-058362
- ACT 058362
- UNII-ULD9ZKE457
- 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea
- ULD9ZKE457
- CHEMBL567303
- Palosuran [INN]
- 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
- ACT058362 (Palosuran)
- GTPL3516
- SCHEMBL1363480
- DTXSID00202406
- WYJCYXOCHXWTHG-UHFFFAOYSA-N
- BCP15786
- BDBM50302272
- ZINC34375693
- AKOS026750332
- 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl-3-(2-methylquinolin-4-yl)urea
- CS-1722
- NCGC00408890-01
- ACT-058362
- palosuranum
- RefChem:169773
- DTXCID60124897
- ACT058362
- MFCD07772352
- ACT 058362; Palosuran
- orb1705555
- SCHEMBL29441424
- AC-35242
- DA-76574
- HY-10655
- MS-27325
- BRD-K07682953-001-01-8
- SCHEMBL29441419
- Palosuran sulfate
- SCHEMBL5265025
Look up PALOSURAN in the interactive SynDRA portal →